References
- Ayerbe J, Lobato RD, Cruz J, Cabrera A. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir 1999; 141: 921-32.
- Black P. 643 meningiomas: current perspective. Neurosurgery 2003; 32: 643-57.
- De Monte F, Marmor E, Al-Mefty O. Meningiomas. In: Kaye AH, editor. Brain tumours. London: Harcourt Publishers; 2001. p. 719-50.
- Jäaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A mutivariate analysis. Surg Neurol 1986; 26: 461-9.
- Franko A, Holjar-Erlic I, Miletic D. Lateral ventricle epidermoid. Radiol Oncol 2008; 42: 66-8.
- Strojan P. Role of radiotherapy in melanoma management. Radiol Oncol 2010; 44: 1-12.
- Torp SH, Lindboe CF, Gronberg BH, Lydersen S, Sundstrom S. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin Neuropathol 2005; 24: 170-4.
- Perry A, Stafford LS, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53 and DNA flow citometry in completely resected primary meningiomas. Cancer 1998; 82: 2262-9.
- Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir 2004; 146: 37-44.
- Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 1993; 33: 212-8.
- Hsu DW, Efird J, Hedley-White ET. Progesterone and estrogene receptors in meningiomas: prognostic considerations. J Neurosurg 1997; 86: 113-20.
- Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, et al. Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 2003; 43: 280-90.
- Friend KE, Radinsky R, McCutcheon IE. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 1999; 91: 93-9.
- Hancq S, Salmon I, Brotchi J, De Witte O, Gabius HJ, Heizmann CW, et al. S100A5: a marker of recurrence in WHO grade I meningiomas. Neuropathol Appl Neurobiol 2004; 30: 78-87.
- Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY. Survivin in brain tumours: an attractive target for immunotherapy. J Neurooncol 2003; 64: 71-6.
- Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 2006; 37: 415-21.
- Puduvalli VK, Li JT, Chen L, McCutcheon IE. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res 2005; 65: 1547-53.
- Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol 2004; 66: 29-37.
- Perret AG, Duthel R, Fotso MJ, Brunon J. Stromelysin-3 is expressed by aggressive meningiomas. Cancer 2002; 94: 765-72.
- Mikkelsen T, Yan PS, Ho KL, Sameni M. Immunolocalization of cathepsin B in human glioma: implications for tumor invasiveness and angiogenesis. J Neurosurg 1995; 83: 285-90.
- Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Rao JS. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Expl Metastasis 1995; 13: 49-56.
- Sivaparvathi M, Yamamoto M, Nicolson GL, Rao JS. Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastasis 1996; 14: 27-34.
- Strojnik T, Kos J, Židanik B, Lah TT. Cathepsin B immunohistochemical staining in tumor and endothelial cells is new prognostic factor in patients with brain tumors. Clin Cancer Res 1999; 5: 559-67.
- Strojan P. Cysteine cathepsins and stefins in head and neck cancer: an update of clinical studies. Radiol Oncol 2008; 42: 69-81.
- Castilla EA, Prayson RA, Abramovich CM, Cohen ML. Immunohistochemical expression of cathepsin D in meningiomas. Am J Clinl Pathol 2003; 119: 123-8.
- Trinkaus M, Vranic A, Dolenc VV, Lah TT. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers 2005; 20: 50-9.
- Trinkaus M, Vranic A, Dolenc VV, Lah TT. Cathepsin L in human meningiomas. Radiol Oncol 2003; 37: 89-99.
- Strojnik T, Zidanik B, Kos J, Lah TT. Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery 2001; 48: 598-605.
- Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85: 2046-56.
- Modha A, Gutin PH: Diagnosis and treatment of atypical and malignant meningiomas: a review. Neurosurgery 2005; 57: 538-50.
- Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 2008; 79: 574-80.
- Nordqvist ACS, Smurawa H, Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg 2001; 95: 839-84.
- Strojnik A. Search of the shortest regimen: fractionation of a fully isoeffective combination of hyperfractionated and hypofractionated treatment. Radiol Oncol 2008; 42: 170-2.